1. Home
  2. STEC vs PASG Comparison

STEC vs PASG Comparison

Compare STEC & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STEC
  • PASG
  • Stock Information
  • Founded
  • STEC 2006
  • PASG 2017
  • Country
  • STEC China
  • PASG United States
  • Employees
  • STEC N/A
  • PASG N/A
  • Industry
  • STEC
  • PASG Biotechnology: Pharmaceutical Preparations
  • Sector
  • STEC
  • PASG Health Care
  • Exchange
  • STEC NYSE
  • PASG Nasdaq
  • Market Cap
  • STEC 29.7M
  • PASG 31.1M
  • IPO Year
  • STEC 2021
  • PASG 2020
  • Fundamental
  • Price
  • STEC $0.97
  • PASG $0.39
  • Analyst Decision
  • STEC
  • PASG Strong Buy
  • Analyst Count
  • STEC 0
  • PASG 3
  • Target Price
  • STEC N/A
  • PASG $7.67
  • AVG Volume (30 Days)
  • STEC 12.1K
  • PASG 323.8K
  • Earning Date
  • STEC 07-01-2025
  • PASG 08-07-2025
  • Dividend Yield
  • STEC N/A
  • PASG N/A
  • EPS Growth
  • STEC N/A
  • PASG N/A
  • EPS
  • STEC N/A
  • PASG N/A
  • Revenue
  • STEC $28,023,000.00
  • PASG N/A
  • Revenue This Year
  • STEC $9,392.20
  • PASG N/A
  • Revenue Next Year
  • STEC N/A
  • PASG N/A
  • P/E Ratio
  • STEC N/A
  • PASG N/A
  • Revenue Growth
  • STEC 50.79
  • PASG N/A
  • 52 Week Low
  • STEC $0.20
  • PASG $0.26
  • 52 Week High
  • STEC $3.25
  • PASG $1.33
  • Technical
  • Relative Strength Index (RSI)
  • STEC 43.73
  • PASG 48.43
  • Support Level
  • STEC $0.97
  • PASG $0.38
  • Resistance Level
  • STEC $1.02
  • PASG $0.52
  • Average True Range (ATR)
  • STEC 0.08
  • PASG 0.04
  • MACD
  • STEC 0.00
  • PASG -0.01
  • Stochastic Oscillator
  • STEC 14.78
  • PASG 11.03

About STEC SANTECH HOLDINGS LIMITED

Santech Holdings Ltd is a customer based technology company. The company is engaged in exploring new opportunities in technology that includes new retail, social e-commerce, metaverse and others.

About PASG Passage Bio Inc.

Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.

Share on Social Networks: